{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:49:11Z","timestamp":1791402551258,"version":"4.3.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Lanzhou City Medical and Health Care Industry Research Project, China","award":["A2023014"],"award-info":[{"award-number":["A2023014"]}]},{"name":"Lanzhou City Medical and Health Care Industry Research Project, China","award":["A2023014"],"award-info":[{"award-number":["A2023014"]}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"crossref","award":["23JRRA1789"],"award-info":[{"award-number":["23JRRA1789"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"crossref","award":["23JRRA1789"],"award-info":[{"award-number":["23JRRA1789"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"crossref","award":["23JRRA1789"],"award-info":[{"award-number":["23JRRA1789"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03434-5","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T08:49:33Z","timestamp":1748162973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Study of target INR achievement, incidence of hemorrhagic complications and affecting factors after during warfarin treatment in western area of China"],"prefix":"10.1038","volume":"15","author":[{"given":"Rui","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"key":"3434_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/0113892002290846240228061506","volume":"25","author":"S Hazra","year":"2024","unstructured":"Hazra, S., Singh, P. A. & Bajwa, N. Safety issues of herb-warfarin interactions. Curr. Drug. Metab. 25, 13\u201327. https:\/\/doi.org\/10.2174\/0113892002290846240228061506 (2024).","journal-title":"Curr. Drug. Metab."},{"key":"3434_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40256-020-00449-3","volume":"21","author":"AR Duraes","year":"2021","unstructured":"Duraes, A. R. et al. Rivaroxaban versus warfarin in patients with mechanical heart valves: Open-label, proof-of-concept trial-the RIWA study. Am. J. Cardiovasc. Drugs 21, 363\u2013371. https:\/\/doi.org\/10.1007\/s40256-020-00449-3 (2021).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"3434_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.36104\/amc.2021.1945","volume":"46","author":"MC Uribe Barrada","year":"2021","unstructured":"Uribe Barrada, M. C., Bustamante-Trespalacios, J. M., Castro-S\u00e1nchez, S. & Arrieta-Bechara, J. C. Seguridad de los anticoagulantes orales en enfermedad renal cr\u00f3nica avanzada. Acta M\u00e9d. Colomb. 46, 18\u201325. https:\/\/doi.org\/10.36104\/amc.2021.1945 (2021).","journal-title":"Acta M\u00e9d. Colomb."},{"key":"3434_CR4","doi-asserted-by":"publisher","first-page":"e0267966","DOI":"10.1371\/journal.pone.0267966","volume":"17","author":"Z Ma","year":"2022","unstructured":"Ma, Z. et al. Warfarin sensitivity is associated with increased hospital mortality in critically Ill patients. PLoS ONE 17, e0267966. https:\/\/doi.org\/10.1371\/journal.pone.0267966 (2022).","journal-title":"PLoS ONE"},{"key":"3434_CR5","doi-asserted-by":"publisher","first-page":"155479","DOI":"10.1016\/j.phymed.2024.155479","volume":"128","author":"L Xue","year":"2024","unstructured":"Xue, L. et al. Warfarin-A natural anticoagulant: A review of research trends for precision medication. Phytomedicine 128, 155479. https:\/\/doi.org\/10.1016\/j.phymed.2024.155479 (2024).","journal-title":"Phytomedicine"},{"key":"3434_CR6","doi-asserted-by":"publisher","first-page":"e2368","DOI":"10.1212\/WNL.0000000000201122","volume":"99","author":"L Shu","year":"2022","unstructured":"Shu, L. et al. Predictors of recurrent venous thrombosis after cerebral venous thrombosis: Analysis of the ACTION-CVT study. Neurology 99, e2368\u2013e2377. https:\/\/doi.org\/10.1212\/WNL.0000000000201122 (2022).","journal-title":"Neurology"},{"key":"3434_CR7","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/FJC.0000000000001048","volume":"78","author":"Q Xu","year":"2021","unstructured":"Xu, Q. et al. Genetic associations with stable warfarin dose requirements in Han Chinese patients. J. Cardiovasc. Pharmacol. 78, e105\u2013e111. https:\/\/doi.org\/10.1097\/FJC.0000000000001048 (2021).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"3434_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12959-022-00416-9","volume":"20","author":"TA Tadesse","year":"2022","unstructured":"Tadesse, T. A., Tegegne, G. T., Yadeta, D., Chelkaba, L. & Fenta, T. G. Anticoagulation control, outcomes, and associated factors in long-term-care patients receiving warfarin in Africa: A systematic review. Thromb. J. 20, 58. https:\/\/doi.org\/10.1186\/s12959-022-00416-9 (2022).","journal-title":"Thromb. J."},{"key":"3434_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2147\/PPA.S156734","volume":"12","author":"X Li","year":"2018","unstructured":"Li, X. et al. Assessment of patients\u2019 warfarin knowledge and anticoagulation control at a joint physician- and pharmacist-managed clinic in China. Patient Prefer. Adherence 12, 783\u2013791. https:\/\/doi.org\/10.2147\/PPA.S156734 (2018).","journal-title":"Patient Prefer. Adherence"},{"key":"3434_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/ehjqcco\/qcab054","volume":"9","author":"Y Guo","year":"2023","unstructured":"Guo, Y. et al. Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation: A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. Eur. Heart J. Qual. Care Clin. Outcomes 9, 169\u2013176. https:\/\/doi.org\/10.1093\/ehjqcco\/qcab054 (2023).","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"3434_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3389\/fphar.2020.01014","volume":"11","author":"Y Ren","year":"2020","unstructured":"Ren, Y. et al. Pharmacogenetic-guided algorithm to improve daily dose of warfarin in elder Han-Chinese population. Front. Pharmacol. 11, 1014. https:\/\/doi.org\/10.3389\/fphar.2020.01014 (2020).","journal-title":"Front. Pharmacol."},{"key":"3434_CR12","doi-asserted-by":"publisher","first-page":"1235331","DOI":"10.3389\/fphar.2023.1235331","volume":"14","author":"X Cai","year":"2023","unstructured":"Cai, X. et al. Application of a warfarin dosing calculator to guide individualized dosing versus empirical adjustment after fixed dosing: a pilot study. Front. Pharmacol. 14, 1235331. https:\/\/doi.org\/10.3389\/fphar.2023.1235331 (2023).","journal-title":"Front. Pharmacol."},{"key":"3434_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2217\/pgs-2022-0038","volume":"23","author":"M Qian","year":"2022","unstructured":"Qian, M. et al. Establishment of a prediction algorithm for the Honghe minority group based on warfarin maintenance dose. Pharmacogenomics 23, 619\u2013626. https:\/\/doi.org\/10.2217\/pgs-2022-0038 (2022).","journal-title":"Pharmacogenomics"},{"key":"3434_CR14","doi-asserted-by":"publisher","first-page":"e28905","DOI":"10.7759\/cureus.28905","volume":"14","author":"B Sun","year":"2022","unstructured":"Sun, B., Yew, P. Y., Wen, Y. F., Chi, C. L. & Straka, R. J. Comparison of the warfarin dosing and outcomes in Hmong versus east Asians patients: Real-world data from an integrated healthcare system. Cureus 14, e28905. https:\/\/doi.org\/10.7759\/cureus.28905 (2022).","journal-title":"Cureus"},{"key":"3434_CR15","doi-asserted-by":"publisher","first-page":"e055407","DOI":"10.1136\/bmjopen-2021-055407","volume":"12","author":"X Wu","year":"2022","unstructured":"Wu, X. et al. Natural population cohort study on long-lived adults: West China longevity and ageing procedure (WCLAP). BMJ Open 12, e055407. https:\/\/doi.org\/10.1136\/bmjopen-2021-055407 (2022).","journal-title":"BMJ Open"},{"key":"3434_CR16","doi-asserted-by":"publisher","first-page":"736","DOI":"10.46234\/ccdcw2020.184","volume":"2","author":"T Xu","year":"2020","unstructured":"Xu, T. & Han, H. Two-week prevalence of disease among the rural elderly\u20146 provinces, China, 2018\u20132019. China CDC Wkly. 2, 736\u2013739. https:\/\/doi.org\/10.46234\/ccdcw2020.184 (2020).","journal-title":"China CDC Wkly."},{"key":"3434_CR17","doi-asserted-by":"publisher","first-page":"e29626","DOI":"10.1097\/MD.0000000000029626","volume":"101","author":"J Li","year":"2022","unstructured":"Li, J. et al. Impact of VKORC1, CYP2C9, CYP1A2, UGT1A1, and GGCX polymorphisms on warfarin maintenance dose: Exploring a new algorithm in South Chinese patients accept mechanical heart valve replacement. Medicine 101, e29626. https:\/\/doi.org\/10.1097\/MD.0000000000029626 (2022).","journal-title":"Medicine"},{"key":"3434_CR18","doi-asserted-by":"publisher","first-page":"14846","DOI":"10.1038\/s41598-024-65048-7","volume":"14","author":"X Xia","year":"2024","unstructured":"Xia, X., Cai, X., Chen, J., Jiang, S. & Zhang, J. Construction of warfarin population pharmacokinetics and pharmacodynamics model in Han population based on Bayesian method. Sci. Rep. 14, 14846. https:\/\/doi.org\/10.1038\/s41598-024-65048-7 (2024).","journal-title":"Sci. Rep."},{"key":"3434_CR19","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.21037\/apm-21-830","volume":"10","author":"L Zhang","year":"2021","unstructured":"Zhang, L., Chen, W. & Gan, D. Analysis of the physiological and pathological factors of hospitalized patients taking warfarin and the correlation between drug interactions and warfarin efficacy. Ann. Palliat. Med. 10, 5400\u20135406. https:\/\/doi.org\/10.21037\/apm-21-830 (2021).","journal-title":"Ann. Palliat. Med."},{"key":"3434_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13104-023-06383-2","volume":"16","author":"B Sombat","year":"2023","unstructured":"Sombat, B. et al. Incidence and risk factors of warfarin therapy complications in community hospitals, central and eastern regions, Thailand: A retrospective, multicenter, cohort study. BMC Res. Notes 16, 104. https:\/\/doi.org\/10.1186\/s13104-023-06383-2 (2023).","journal-title":"BMC Res. Notes"},{"key":"3434_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.14744\/SEMB.2019.76993","volume":"54","author":"N Demir","year":"2020","unstructured":"Demir, N. et al. Determining INR awareness of the patients who use warfarin and rates of achieving the target dosage. Sisli Etfal Hastan. Tip Bul. 54, 357\u2013363. https:\/\/doi.org\/10.14744\/SEMB.2019.76993 (2020).","journal-title":"Sisli Etfal Hastan. Tip Bul."},{"key":"3434_CR22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s11096-020-01043-y","volume":"42","author":"H Cao","year":"2020","unstructured":"Cao, H. et al. The effect of warfarin knowledge on anticoagulation control among patients with heart valve replacement. Int. J. Clin. Pharm. 42, 861\u2013870. https:\/\/doi.org\/10.1007\/s11096-020-01043-y (2020).","journal-title":"Int. J. Clin. Pharm."},{"key":"3434_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/ijpp.12584","volume":"28","author":"JB Liang","year":"2020","unstructured":"Liang, J. B. et al. Impact of a pharmacist-led education and follow-up service on anticoagulation control and safety outcomes at a tertiary hospital in China: A randomised controlled trial. Int. J. Pharm. Pract. 28, 97\u2013106. https:\/\/doi.org\/10.1111\/ijpp.12584 (2020).","journal-title":"Int. J. Pharm. Pract."},{"key":"3434_CR24","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3389\/fphar.2020.01056","volume":"11","author":"LR Marcatto","year":"2020","unstructured":"Marcatto, L. R. et al. Evaluation of the long-term impact on quality after the end of pharmacist-driven warfarin therapy management in patients with poor quality of anticoagulation therapy. Front. Pharmacol. 11, 1056. https:\/\/doi.org\/10.3389\/fphar.2020.01056 (2020).","journal-title":"Front. Pharmacol."},{"key":"3434_CR25","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2147\/RMHP.S248222","volume":"13","author":"S Alghadeeer","year":"2020","unstructured":"Alghadeeer, S., Alzahrani, A. A., Alalayet, W. Y., Alkharashi, A. A. & Alarifi, M. N. Anticoagulation control of warfarin in pharmacist-led clinics versus physician-led clinics: A prospective observational study. Risk Manag. Healthc. Policy 13, 1175\u20131179. https:\/\/doi.org\/10.2147\/RMHP.S248222 (2020).","journal-title":"Risk Manag. Healthc. Policy"},{"key":"3434_CR26","doi-asserted-by":"publisher","first-page":"101795","DOI":"10.1016\/j.jsps.2023.101795","volume":"31","author":"M Almuqbil","year":"2023","unstructured":"Almuqbil, M. et al. Comparison of medical documentation between pharmacist-led anticoagulation clinics and physician-led anticoagulation clinics: A retrospective study. Saudi Pharm. J. 31, 101795. https:\/\/doi.org\/10.1016\/j.jsps.2023.101795 (2023).","journal-title":"Saudi Pharm. J."},{"key":"3434_CR27","first-page":"728","volume":"42","author":"L Jie","year":"2023","unstructured":"Jie, L. et al. A study on the current status of clinical pharmacy service development in 122 medical institutions in Gansu province. Gansu Med. J. 42, 728\u2013731 (2023).","journal-title":"Gansu Med. J."},{"key":"3434_CR28","doi-asserted-by":"publisher","first-page":"673302","DOI":"10.3389\/fphar.2021.673302","volume":"12","author":"N Wang","year":"2021","unstructured":"Wang, N. et al. Physician-pharmacist collaborative clinic model to improve anticoagulation quality in atrial fibrillation patients receiving warfarin: An analysis of time in therapeutic range and a nomogram development. Front. Pharmacol. 12, 673302. https:\/\/doi.org\/10.3389\/fphar.2021.673302 (2021).","journal-title":"Front. Pharmacol."},{"key":"3434_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1253\/circj.CJ-19-0898","volume":"84","author":"KI Hiasa","year":"2020","unstructured":"Hiasa, K. I. et al. Age-related differences in the clinical characteristics and treatment of elderly patients with atrial fibrillation in Japan\u2014insight from the ANAFIE (All Nippon AF In Elderly) registry. Circ. J. 84, 388\u2013396. https:\/\/doi.org\/10.1253\/circj.CJ-19-0898 (2020).","journal-title":"Circ. J."},{"key":"3434_CR30","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/joa3.12608","volume":"37","author":"Y Guo","year":"2021","unstructured":"Guo, Y. et al. One-year follow-up results of the optimal thromboprophylaxis in elderly Chinese patients with atrial fibrillation (ChiOTEAF) REGISTRY. J. Arrhythm. 37, 1227\u20131239. https:\/\/doi.org\/10.1002\/joa3.12608 (2021).","journal-title":"J. Arrhythm."},{"key":"3434_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1055\/s-0040-1716540","volume":"121","author":"G Boriani","year":"2021","unstructured":"Boriani, G. et al. Edoxaban versus Warfarin in patients with atrial fibrillation at the extremes of body weight: An analysis from the ENGAGE AF-TIMI 48 trial. Thromb. Haemost. 121, 140\u2013149. https:\/\/doi.org\/10.1055\/s-0040-1716540 (2021).","journal-title":"Thromb. Haemost."},{"key":"3434_CR32","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/cpt.1819","volume":"107","author":"TA Miano","year":"2020","unstructured":"Miano, T. A. et al. The magnitude of the warfarin-amiodarone drug-drug interaction varies with renal function: A propensity-matched cohort study. Clin. Pharmacol. Ther. 107, 1446\u20131456. https:\/\/doi.org\/10.1002\/cpt.1819 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"3434_CR33","doi-asserted-by":"publisher","first-page":"e20190025","DOI":"10.1590\/1678-4685-GMB-2019-0025","volume":"43","author":"MR Botton","year":"2020","unstructured":"Botton, M. R. et al. Identification of environmental and genetic factors that influence warfarin time in therapeutic range. Genet. Mol. Biol. 43, e20190025. https:\/\/doi.org\/10.1590\/1678-4685-GMB-2019-0025 (2020).","journal-title":"Genet. Mol. Biol."},{"key":"3434_CR34","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00228-020-02856-6","volume":"76","author":"DM Rydberg","year":"2020","unstructured":"Rydberg, D. M., Linder, M., Malmstrom, R. E. & Andersen, M. Risk factors for severe bleeding events during warfarin treatment: The influence of sex, age, comorbidity and co-medication. Eur. J. Clin. Pharmacol. 76, 867\u2013876. https:\/\/doi.org\/10.1007\/s00228-020-02856-6 (2020).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"3434_CR35","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/ehf2.14277","volume":"10","author":"S Kawanami","year":"2023","unstructured":"Kawanami, S. et al. Predictors of bleeding events in acute decompensated heart failure patients with antithrombotic therapy: AURORA study. ESC Heart Fail. 10, 1114\u20131121. https:\/\/doi.org\/10.1002\/ehf2.14277 (2023).","journal-title":"ESC Heart Fail."},{"key":"3434_CR36","doi-asserted-by":"publisher","first-page":"e068037","DOI":"10.1136\/bmj-2021-068037","volume":"375","author":"H Ahmed","year":"2021","unstructured":"Ahmed, H., Whitaker, H., Farewell, D., Hippisley-Cox, J. & Noble, S. Respiratory tract infection and risk of bleeding in oral anticoagulant users: Self-controlled case series. BMJ 375, e068037. https:\/\/doi.org\/10.1136\/bmj-2021-068037 (2021).","journal-title":"BMJ"},{"key":"3434_CR37","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1111\/bcp.14833","volume":"87","author":"M Wang","year":"2021","unstructured":"Wang, M. et al. Drug-drug interactions with warfarin: A systematic review and meta-analysis. Br. J. Clin. Pharmacol. 87, 4051\u20134100. https:\/\/doi.org\/10.1111\/bcp.14833 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3434_CR38","doi-asserted-by":"publisher","first-page":"e13382","DOI":"10.1111\/ijcp.13382","volume":"73","author":"V Bertram","year":"2019","unstructured":"Bertram, V., Yeo, K., Anoopkumar-Dukie, S. & Bernaitis, N. Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. Int. J. Clin. Pract. 73, e13382. https:\/\/doi.org\/10.1111\/ijcp.13382 (2019).","journal-title":"Int. J. Clin. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03434-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T08:49:34Z","timestamp":1748162974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03434-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3434"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03434-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The aim of this study was to investigate the achievement of target international normalized ratio (INR) after warfarin treatment and the factors influencing hemorrhagic complications in western area of China. We are committed to abiding by relevant ethics and legal regulations, especially those relating to informed consent and privacy protection. Informed consent: we have obtained the informed consent of the subjects, detailing the purpose, process, possible risks and benefits of the study, and ensuring their voluntary participation. We ensure that informed consent is clear, free and pressure-free, and that participants have the right to withdraw their consent and terminate their participation at any time. Privacy protection: we strictly abide by the relevant privacy protection laws and guidelines, and take necessary measures to ensure the confidentiality and security of participants\u2019 personal information and data. We are limited to collecting the necessary information related to the purpose of the research and anonymizing and encrypting the data to protect the privacy of the participants. Ethical review and approval: the studies of human participants, human materials or human data in this study were conducted in accordance with the Helsinki Declaration and approved by the Ethics Committee of Lanzhou first people\u2019s Hospital. Ethics Number: 2024A-24. We will follow the requirements and recommendations of ethical approval and maintain timely communication with the Ethics Committee during the research process. If you have any questions or concerns about the research process or ethical issues, please feel free to contact us. We will be more than happy to answer your questions and solve any possible problems. We attach importance to the rights and safety of participants and will always ensure that our research is in line with ethics and legal requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Since the manuscript does not contain information or images that may lead to the identity of the research participant, it is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"18200"}}